PortalPublikationenMucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal...

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study

Standard

Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. / Striefler, Jana Käthe; Riess, Hanno; Lohneis, Philipp; Bischoff, Sven; Kurreck, Annika; Modest, Dominik Paul; Bahra, Marcus; Oettle, Helmut; Sinn, Marianne; Bläker, Henrik; Denkert, Carsten; Stintzing, Sebastian; Sinn, Bruno Valentin; Pelzer, Uwe.

in: FRONT ONCOL, Jahrgang 11, 670396, 2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Striefler, JK, Riess, H, Lohneis, P, Bischoff, S, Kurreck, A, Modest, DP, Bahra, M, Oettle, H, Sinn, M, Bläker, H, Denkert, C, Stintzing, S, Sinn, BV & Pelzer, U 2021, 'Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study', FRONT ONCOL, Jg. 11, 670396. https://doi.org/10.3389/fonc.2021.670396

APA

Striefler, J. K., Riess, H., Lohneis, P., Bischoff, S., Kurreck, A., Modest, D. P., Bahra, M., Oettle, H., Sinn, M., Bläker, H., Denkert, C., Stintzing, S., Sinn, B. V., & Pelzer, U. (2021). Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. FRONT ONCOL, 11, [670396]. https://doi.org/10.3389/fonc.2021.670396

Vancouver

Striefler JK, Riess H, Lohneis P, Bischoff S, Kurreck A, Modest DP et al. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. FRONT ONCOL. 2021;11. 670396. https://doi.org/10.3389/fonc.2021.670396

Bibtex

@article{d61c560176e444f08d9d4cf089fe29ba,
title = "Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study",
abstract = "Background: The Mucin-family protein, MUC1, impacts on carcinogenesis and tumor invasion. We evaluated the impact of MUC1 expression on outcome in a cohort of 158 patients with resected pancreatic ductal adenocarcinomas (PDAC) in the CONKO-001 study (adjuvant gemcitabine [gem] vs. observation [obs]).Methods: The percentage of MUC1-positive tumor cells by immunohistochemistry (IHC) and the staining intensity were evaluated by two observers blinded to outcome. The numeric values of both parameters were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12. The level of MUC1 expression was defined as follows: IRS 0-4 (low) vs IRS >4 (high). Outcomes in terms of disease-free (DFS) and overall survival (OS) were evaluated by Kaplan-Meier method, log-rank tests and Cox regressions.Results: In total, tumors of 158 study patients were eligible for immunohistochemistry of MUC1. High cytoplasmic MUC1 expression was associated with impaired DFS and OS in the overall study population (hazard ratio (HR) for DFS: 0.49, 95% CI 0.31 to 0.78, p = .003; HR for OS: 0.46, 95% CI 0.29 to 0.73, p = .001). In the study arms, prognostic effects of MUC1 were also evident in the observation group (HR for DFS: 0.55; 95% CI 0.29 to 1.04, p = .062; HR for OS: 0.34, 95% CI 0.17 to 0.67, p = .001) and trending in the gem group (HR for DFS: 0.48, 95% CI 0.24 to 0.95, p = .041; HR for OS: 0.56, 95% CI 0.28 to1.11, p = .093).Conclusion: Our data suggest that MUC1 expression is a powerful prognostic marker in patients with PDAC after curatively intended resection.",
author = "Striefler, {Jana K{\"a}the} and Hanno Riess and Philipp Lohneis and Sven Bischoff and Annika Kurreck and Modest, {Dominik Paul} and Marcus Bahra and Helmut Oettle and Marianne Sinn and Henrik Bl{\"a}ker and Carsten Denkert and Sebastian Stintzing and Sinn, {Bruno Valentin} and Uwe Pelzer",
note = "Copyright {\textcopyright} 2021 Striefler, Riess, Lohneis, Bischoff, Kurreck, Modest, Bahra, Oettle, Sinn, Bl{\"a}ker, Denkert, Stintzing, Sinn and Pelzer.",
year = "2021",
doi = "10.3389/fonc.2021.670396",
language = "English",
volume = "11",
journal = "FRONT ONCOL",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study

AU - Striefler, Jana Käthe

AU - Riess, Hanno

AU - Lohneis, Philipp

AU - Bischoff, Sven

AU - Kurreck, Annika

AU - Modest, Dominik Paul

AU - Bahra, Marcus

AU - Oettle, Helmut

AU - Sinn, Marianne

AU - Bläker, Henrik

AU - Denkert, Carsten

AU - Stintzing, Sebastian

AU - Sinn, Bruno Valentin

AU - Pelzer, Uwe

N1 - Copyright © 2021 Striefler, Riess, Lohneis, Bischoff, Kurreck, Modest, Bahra, Oettle, Sinn, Bläker, Denkert, Stintzing, Sinn and Pelzer.

PY - 2021

Y1 - 2021

N2 - Background: The Mucin-family protein, MUC1, impacts on carcinogenesis and tumor invasion. We evaluated the impact of MUC1 expression on outcome in a cohort of 158 patients with resected pancreatic ductal adenocarcinomas (PDAC) in the CONKO-001 study (adjuvant gemcitabine [gem] vs. observation [obs]).Methods: The percentage of MUC1-positive tumor cells by immunohistochemistry (IHC) and the staining intensity were evaluated by two observers blinded to outcome. The numeric values of both parameters were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12. The level of MUC1 expression was defined as follows: IRS 0-4 (low) vs IRS >4 (high). Outcomes in terms of disease-free (DFS) and overall survival (OS) were evaluated by Kaplan-Meier method, log-rank tests and Cox regressions.Results: In total, tumors of 158 study patients were eligible for immunohistochemistry of MUC1. High cytoplasmic MUC1 expression was associated with impaired DFS and OS in the overall study population (hazard ratio (HR) for DFS: 0.49, 95% CI 0.31 to 0.78, p = .003; HR for OS: 0.46, 95% CI 0.29 to 0.73, p = .001). In the study arms, prognostic effects of MUC1 were also evident in the observation group (HR for DFS: 0.55; 95% CI 0.29 to 1.04, p = .062; HR for OS: 0.34, 95% CI 0.17 to 0.67, p = .001) and trending in the gem group (HR for DFS: 0.48, 95% CI 0.24 to 0.95, p = .041; HR for OS: 0.56, 95% CI 0.28 to1.11, p = .093).Conclusion: Our data suggest that MUC1 expression is a powerful prognostic marker in patients with PDAC after curatively intended resection.

AB - Background: The Mucin-family protein, MUC1, impacts on carcinogenesis and tumor invasion. We evaluated the impact of MUC1 expression on outcome in a cohort of 158 patients with resected pancreatic ductal adenocarcinomas (PDAC) in the CONKO-001 study (adjuvant gemcitabine [gem] vs. observation [obs]).Methods: The percentage of MUC1-positive tumor cells by immunohistochemistry (IHC) and the staining intensity were evaluated by two observers blinded to outcome. The numeric values of both parameters were multiplied, resulting in an immunoreactivity score (IRS) ranging from 0 to 12. The level of MUC1 expression was defined as follows: IRS 0-4 (low) vs IRS >4 (high). Outcomes in terms of disease-free (DFS) and overall survival (OS) were evaluated by Kaplan-Meier method, log-rank tests and Cox regressions.Results: In total, tumors of 158 study patients were eligible for immunohistochemistry of MUC1. High cytoplasmic MUC1 expression was associated with impaired DFS and OS in the overall study population (hazard ratio (HR) for DFS: 0.49, 95% CI 0.31 to 0.78, p = .003; HR for OS: 0.46, 95% CI 0.29 to 0.73, p = .001). In the study arms, prognostic effects of MUC1 were also evident in the observation group (HR for DFS: 0.55; 95% CI 0.29 to 1.04, p = .062; HR for OS: 0.34, 95% CI 0.17 to 0.67, p = .001) and trending in the gem group (HR for DFS: 0.48, 95% CI 0.24 to 0.95, p = .041; HR for OS: 0.56, 95% CI 0.28 to1.11, p = .093).Conclusion: Our data suggest that MUC1 expression is a powerful prognostic marker in patients with PDAC after curatively intended resection.

U2 - 10.3389/fonc.2021.670396

DO - 10.3389/fonc.2021.670396

M3 - SCORING: Journal article

C2 - 34386419

VL - 11

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

M1 - 670396

ER -